STADA

Overview

Overview

STADA is a publicly traded, international
company with a focus on the healthcare market.

STADA Business Model

  • Focus on products with off-patent active pharmaceutical ingredients in the health care market concentrating on the pharmaceutical market
  • Core segments

    • Generics (58% share of Group sales)
    • Branded Products (40% share of Group sales)

  • Strategic success factors
    • Good positioning in long-term growth markets
    • Strong presence in Europe and, at the same time, an internationalization strategy with a focus on high-growth markets and branded products
    • Comprehensive generics portfolio, selected biosimilars and branded products with an attractive margin
    • Successful product development with a well-filled product pipeline
    • International sales structure
    • Functional organizational structure with strong local market presence
    • Efficient cost management including a culture of continuous cost optimization
    • Highly trained and committed employees all over the world

     

STADA Financial Year 2015

  • Group sales increase by 3% to € 2.12 billion – Group sales adjusted for currency and portfolio effects grow by 4%
  • Reported key earnings figures
    • Reported EBITDA declines by 10% to € 377.1 million
    • Reported net income increases by 71% to € 110.4 million
    • Earnings per share increase by 67% to € 1.79
  • All adjusted key earnings figures
    • Adjusted EBITDA declines by 10% to € 389.4 million
    • Adjusted net income records a decrease by 11% to € 165.8 million
    • Adjusted earnings per share decrease by 13% to € 2.69
  • Pleasing development in Central Europe with sales growth of 5% and in Asia/Pacific & MENA with a sales increase of 55%
  • Further expansion of the self-pay patient portfolio from sales growth of 7% in branded products – share of branded products in adjusted operating profit of core segments amounts to 48.5%
  • Strong product development with a total of 578 product launches
  • Further value-enhancing acquisitions to strengthen the branded products portfolio and Generics segment
  • Promising cooperation in the aesthetics area
  • Successful placement of another corporate bond in the amount of € 300 million
  • Increase of STADA share price by 48%
  • Recommendation for a dividend increase of 6% to € 0.70 per STADA share

STADA Outlook

  • Outlook for 2016
    • Slight growth in Group sales adjusted for currency and portfolio effects
    • Slight growth in adjusted EBITDA and adjusted net income
    • Ratio of net debt, excluding further acquisitions, to adjusted EBITDA at a level of nearly 3


     

 

 

Quality at STADA

Quality at STADA

Quality and responsibility to all who use our products or services is a fundamental part of our corporate strategy.

Learn more

Career at STADA

Career at STADA

STADA's employees, with their extensive expertise, their experience and their strong commitment, play an important part in the longstanding success of the Group.

Learn more

Media Relations

Media Relations

In addition to press releases on current issues Journalists can find background information on areas such as personnel, organizational structure, products and manufacturing.

Learn more

Career at STADA

Career at STADA

STADA's employees, with their extensive expertise, their experience and their strong commitment, play an important part in the longstanding success of the Group.

Learn more

Investor Relations

Investor Relations

Here you can find all the facts and background information about the STADA securities.

Lern more

Sustainability

Sustainability

For STADA "All the best" means taking responsibility.

Learn more

entdecken